PARP1 and ovarian carcinoma: More importantly, our study provides a theoretical basis for MRE11:p.K464R mutation as a specific indicator for resistance monitoring of Olaparib, which is expected to optimize the application performance of PARP inhibitors and achieve more accurate treatment and prognosis for ovarian cancer.